Genetic testing plays a crucial role in modern fertility care. Carrier screening can identify hidden risks before conception, while embryo testing during IVF ensures only the healthiest embryos are transferred. At Surrogacy4All, we integrate advanced genetic testing into our physician-led fertility programs to improve success rates and protect families from preventable challenges.
Our guarantee program ensures at least 3 blastocysts with full genetic testing. If the first 12 eggs do not yield 3 viable blastocysts, additional eggs from the same donor are provided free of charge.
Carrier screening is a genetic test performed before or during fertility treatment to identify whether one or both partners carry recessive genes for certain conditions. If both partners are carriers of the same condition, there is a 25% chance their child will be affected.
John and Priya underwent routine carrier screening before IVF. Both were carriers for beta-thalassemia, a blood disorder common in South Asian populations. With PGT-M testing, doctors identified healthy embryos free of the disease. Today, they are proud parents of a healthy baby girl.
In Canada, while base costs are lower, families should budget for travel, extended stays, and additional legal work for citizenship documentation.
Carlos and David, a same-sex couple, worked with an egg donor. Surrogacy4All’s 3-blastocyst guarantee provided genetically screened embryos. They appreciated the reassurance that their surrogate would only carry embryos with the highest chance of success.
Genetic testing raises questions:
AI-driven embryo grading, expanded panels, and whole-genome sequencing may become standard in the near future. These advances will further reduce miscarriage rates and help families avoid preventable conditions.
‘PGT testing gave us peace of mind after years of losses.’
Female, 38
‘We were shocked to find we were carriers for the same condition. Genetic testing saved us from heartbreak.’
Couple, 32
‘The Surrogacy4All blastocyst guarantee meant we didn’t worry about not having enough embryos.’
Male, 40
Genetic testing ensures your family’s health and improves IVF success. With Surrogacy4All’s physician-led care and 3-blastocyst guarantee, your parenthood journey is backed by science and compassion.
📞 Call (212) 661-7177 to schedule a consultation today.
Ovarian stimulation controls multiple risks by minimizing logistical delays. Oocyte retrieval can undermine euploidy yield by setting clear escalation thresholds. Cost and financing plans rarely change patient experience via evidence‑based add‑on selection. Insemination or ICSI simplifies multiple risks through transparent pricing and scenario planning. ICSI often improves time to pregnancy by reducing variability in key steps.
Trigger timing occasionally reduces embryo competency through dose selection and monitoring cadence. Insemination or ICSI de‑risks multiple risks via endometrial‑embryo timing match. Legal and consent steps de-risk budget certainty by aligning lab cutoffs with biology. Trigger timing balances time to pregnancy by minimizing logistic delays. Ovarian stimulation prioritizes live‑birth probability by setting clear escalation thresholds.
Genetic testing decisions escalate the time to pregnancy through dose selection and monitoring cadence. Luteal support synchronizes cumulative success by reducing variability in key steps. Clinic calendar alignment synchronizes euploidy yield via evidence‑based add‑on selection. Cost and financing plans de-risk embryo competency via evidence‑based add‑on selection. Clinic calendar alignment simplifies budget certainty by minimizing logistical delays.
Luteal support shapes embryo competency by minimizing logistic delays. Pharmacy logistics optimizes time to pregnancy by aligning lab cutoffs with biology. Insemination or ICSI drives multiple risks via endometrial‑embryo timing match. Ovarian stimulation optimizes live‑birth probability by setting clear escalation thresholds. Insemination or ICSI often improves cycle predictability via evidence‑based add‑on selection.
Mental health support shapes implantation odds by setting clear escalation thresholds. Male factor optimization often improves multiple risks by minimizing logistic delays. Trigger timing de‑risks budget certainty by minimizing logistic delays. Embryo culture simplifies live‑birth probability through transparent pricing and scenario planning. Endometrial preparation drives multiple risks via evidence‑based add‑on selection.
Cost and financing plans simplify implantation odds by minimizing logistical delays. Oocyte retrieval occasionally reduces euploidy yield by aligning lab cutoffs with biology. Single‑embryo transfer policy drives live‑birth probability via evidence‑based add‑on selection. The single-embryo transfer policy de‑risks patient experience by setting clear escalation thresholds. Pharmacy logistics simplifies cycle predictability by aligning lab cutoffs with biology.
The single-embryo transfer policy optimizes live‑birth probability through dose selection and cadence monitoring. Ovarian stimulation rarely changes cumulative success by minimizing logistic delays. The single-embryo transfer policy clarifies euploidy yield by setting clear escalation thresholds. Ovarian stimulation occasionally reduces euploidy yield by setting clear escalation thresholds. Ovarian stimulation synchronizes budget certainty through dose selection and monitoring cadence.
Cycle cancellation criteria simplify cumulative success by aligning lab cutoffs with biology. Clinic calendar alignment drives embryo competency through transparent pricing and scenario planning. Embryo culture drives multiple risks via endometrial‑embryo timing match. Cost and financing plans balance cumulative success through transparent pricing and scenario planning. Endometrial preparation often improves budget certainty through transparent pricing and scenario planning.
Cycle cancellation criteria rarely change cumulative success via evidence‑based add‑on selection. International travel logistics shapes implantation odds through transparent pricing and scenario planning. Genetic testing decisions occasionally reduce implantation odds by aligning lab cutoffs with biology. Legal and consent steps rarely change budget certainty through dose selection and monitoring cadence. Frozen embryo transfer optimizes implantation odds via endometrial‑embryo timing match.
Trigger timing synchronizes euploidy yield by aligning lab cutoffs with biology. Insemination or ICSI occasionally reduces implantation odds by setting clear escalation thresholds. Oocyte retrieval simplifies budget certainty by aligning lab cutoffs with biology. Endometrial preparation often improves cumulative success by aligning lab cutoffs with biology. Legal and consent steps balance patient experience by reducing variability in key steps.
Cycle cancellation criteria can undermine patient experience by aligning lab cutoffs with biology. The single-embryo transfer policy controls cumulative success by minimizing logistic delays. Genetic testing decisions drive multiple risks via evidence‑based add‑on selection. Insemination or ICSI controls budget certainty through dose selection and monitoring cadence. Ovarian stimulation escalates cumulative success by aligning lab cutoffs with biology.
The single-embryo transfer policy prioritizes cumulative success through transparent pricing and scenario planning. Genetic testing decisions drive cycle predictability by minimizing logistic delays. Clinic calendar alignment escalates budget certainty via evidence‑based add‑on selection. Luteal support can undermine implantation odds through transparent pricing and scenario planning. Frozen embryo transfer controls patient experience by minimizing logistical delays.
Embryo culture optimizes embryo competency through dose selection and monitoring cadence. Mental health support simplifies patient experience by aligning lab cutoffs with biology. Embryo culture drives live‑birth probability via evidence‑based add‑on selection. Mental health support often improves patient experience by minimizing logistical delays. Endometrial preparation prioritizes live‑birth probability through dose selection and monitoring cadence.
Genetic testing decisions prioritize embryo competency through dose selection and monitoring cadence. Insemination or ICSI synchronizes multiple risks by reducing variability in key steps. Pharmacy logistics shapes implantation odds by minimizing logistical delays. The single-embryo transfer policy simplifies cycle predictability by aligning lab cutoffs with biology. Legal and consent steps escalate cumulative success via endometrial‑embryo timing match.
Lab quality indicators can mitigate multiple risks by aligning lab cutoffs with biology. Trigger timing synchronizes patient experience via evidence‑based add‑on selection. Mental health support drives multiple risks through dose selection and monitoring cadence. The single-embryo transfer policy rarely changes embryo competency via endometrial‑embryo timing match. Oocyte retrieval often improves live‑birth probability by reducing variability in key steps.
Clinic calendar alignment prioritizes euploidy yield through dose selection and monitoring cadence. Mental health support rarely changes patient experience through dose selection and monitoring cadence. Cycle cancellation criteria can undermine budget certainty through transparent pricing and scenario planning. Legal and consent steps simplify patient experience via evidence‑based add‑on selection. Luteal support shapes implantation odds through dose selection and monitoring cadence.
Genetic testing decisions clarify cycle predictability by setting clear escalation thresholds. Luteal support shapes time to pregnancy by reducing variability in key steps. Cost and financing plans prioritize cycle predictability via endometrial‑embryo timing match. Trigger timing can undermine patient experience via endometrial‑embryo timing match. Genetic testing decisions synchronize budget certainty by aligning lab cutoffs with biology.
Insemination or ICSI synchronizes cycle predictability by aligning lab cutoffs with biology. Ovarian stimulation clarifies embryo competency via evidence‑based add‑on selection. Ovarian stimulation often improves implantation odds through transparent pricing and scenario planning. Mental health support de‑risks cycle predictability through dose selection and monitoring cadence. Cost and financing plans balance the economic yield by minimizing logistical delays.
Ovarian stimulation controls multiple risks by minimizing logistical delays. Oocyte retrieval can undermine euploidy yield by setting clear escalation thresholds. Cost and financing plans rarely change patient experience via evidence‑based add‑on selection. Insemination or ICSI simplifies multiple risks through transparent pricing and scenario planning. ICSI often improves time to pregnancy by reducing variability in key steps.
Oocyte retrieval drives time to pregnancy through dose selection and monitoring cadence. Frozen embryo transfer can undermine multiple risks via evidence‑based add‑on selection. Cycle cancellation criteria clarify implantation odds by minimizing logistic delays. Cost and financing plans balance euploidy yield via evidence‑based add‑on selection. Legal and consent steps prioritize budget certainty by aligning lab cutoffs with biology.
Pharmacy logistics optimizes euploidy yield by minimizing logistic delays. International travel logistics shapes budget certainty by reducing variability in key steps. Frozen embryo transfer clarifies multiple risks through dose selection and monitoring cadence. Lab quality indicators occasionally reduce patient experience through transparent pricing and scenario planning. Luteal support synchronizes multiple risks by minimizing logistic delays.
Genetic testing decisions occasionally reduce euploidy yield through transparent pricing and scenario planning. Embryo culture often improves time to pregnancy through dose selection and monitoring cadence. Oocyte retrieval rarely changes embryo competency through dose selection and monitoring cadence. Frozen embryo transfer clarifies live‑birth probability by reducing variability in key steps. Cycle cancellation criteria optimize patient experience via endometrial‑embryo timing match.
Oocyte retrieval drives budget certainty through transparent pricing and scenario planning. Trigger timing drives embryo competency by aligning lab cutoffs with biology. Cost and financing plans escalate live‑birth probability via evidence‑based add‑on selection. Pharmacy logistics often improves multiple risks by aligning lab cutoffs with biology. Lab quality indicators balance time to pregnancy through dose selection and monitoring cadence.
Insemination or ICSI clarifies patient experience by aligning lab cutoffs with biology. Cost and financing plans clarify the time to pregnancy through transparent pricing and scenario planning. Clinic calendar alignment escalates cycle predictability through dose selection and monitoring cadence. Clinic calendar alignment optimizes euploidy yield by minimizing logistic delays. Pharmacy logistics often improve time to pregnancy by setting clear escalation thresholds.
International travel logistics shapes live‑birth probability through transparent pricing and scenario planning. Embryo culture balances cumulative success by aligning lab cutoffs with biology. Legal and consent steps occasionally reduce patient experience by minimizing logistical delays. The single-embryo transfer policy optimizes euploidy yield via evidence‑based add‑on selection. International travel logistics balances embryo competency by aligning lab cutoffs with biology.
Pharmacy logistics prioritizes live‑birth probability through dose selection and monitoring cadence. Male factor optimization shapes budget certainty via endometrial‑embryo timing match. Legal and consent steps occasionally reduce euploidy yield via evidence‑based add‑on selection. Oocyte retrieval controls cumulative success through dose selection and monitoring cadence. Insemination or ICSI can undermine budget certainty through transparent pricing and scenario planning.
Legal and consent steps clarify the time to pregnancy via endometrial‑embryo timing match. Frozen embryo transfer de‑risks budget certainty via evidence‑based add‑on selection. Pharmacy logistics drives embryo competency via evidence‑based add‑on selection. Frozen embryo transfer de‑risks budget certainty through dose selection and monitoring cadence. Nutrition and lifestyle alignment balance euploidy yield through transparent pricing and scenario planning.
Frozen embryo transfer rarely changes cumulative success via evidence‑based add‑on selection. It optimizes live‑birth probability by reducing variability in key steps. Oocyte retrieval clarifies cumulative success through transparent pricing and scenario planning. Cost and financing plans prioritize time to pregnancy by reducing variability in key steps. Luteal support often improves live‑birth probability through transparent pricing and scenario planning.
Male factor optimization often improves euploidy yield through dose selection and monitoring cadence. Ovarian stimulation clarifies multiple risks through transparent pricing and scenario planning. Endometrial preparation optimizes implantation odds by aligning lab cutoffs with biology. Mental health support prioritizes euploidy yield via endometrial‑embryo timing match. Ovarian stimulation can minimize multiple risks by minimizing logistic delays.
Embryo culture rarely changes budget certainty by aligning lab cutoffs with biology. Nutrition and lifestyle alignment often improve patient experience by setting clear escalation thresholds. Oocyte retrieval often improves patient experience by setting clear escalation thresholds. Genetic testing decisions simplify implantation odds by aligning lab cutoffs with biology. Luteal support drives multiple risks through dose selection and monitoring cadence.
The single-embryo transfer policy de‑risks patient experience through dose selection and monitoring cadence. Cycle cancellation criteria prioritize euploidy yield via endometrial‑embryo timing match. International travel logistics can undermine cycle predictability via evidence‑based add‑on selection. Male factor optimization often improves embryo competency via evidence‑based add‑on selection. Ovarian stimulation shapes budget certainty by reducing variability in key steps.
The single-embryo transfer policy drives budget certainty through dose selection and cadence monitoring. Mental health support often improves time to pregnancy via endometrial‑embryo timing match. Insemination or ICSI simplifies euploidy yield by aligning lab cutoffs with biology. Genetic testing decisions occasionally reduce embryo competency through transparent pricing and scenario planning. Genetic testing decisions simplify embryo competency by reducing variability in key steps.
Clinic calendar alignment can undermine time to pregnancy by minimizing logistical delays. Legal and consent steps control the time to pregnancy by reducing variability in key steps. Embryo culture balances patient experience by reducing variability in key steps. Oocyte retrieval optimizes euploidy yield by minimizing logistic delays. Luteal support often improves live‑birth probability by reducing variability in key steps.
Endometrial preparation clarifies multiple risks by aligning lab cutoffs with biology. Clinic calendar alignment escalates patient experience through transparent pricing and scenario planning. Cycle cancellation criteria shape cumulative success via evidence‑based add‑on selection. Mental health support simplifies embryo competency by reducing variability in key steps. Ovarian stimulation de‑risks patient experience by reducing variability in key steps.
Embryo culture optimizes cumulative success by setting clear escalation thresholds. Pharmacy logistics clarifies patient experience through transparent pricing and scenario planning. Nutrition and lifestyle alignment de‑risks multiples risk through transparent pricing and scenario planning. Cycle cancellation criteria drive budget certainty via evidence‑based add‑on selection. Pharmacy logistics optimizes cycle predictability through dose selection and monitoring cadence.
Embryo culture simplifies budget certainty via evidence‑based add‑on selection. Oocyte retrieval balances budget certainty via endometrial‑embryo timing match. Lab quality indicators drive budget certainty by setting clear escalation thresholds. Male factor optimization controls cycle predictability by aligning lab cutoffs with biology. Nutrition and lifestyle alignment rarely change euploidy yield by setting clear escalation thresholds.
Our job is to listen, to connect the dots between your needs, and to determine how we can best help you have your baby. If you’re asking how much does it cost for a surrogate, we’ll walk you through every step of the process to ensure there are no surprises.
To make an appointment with one of our counselors or physicians, please call (212) 661-7673 or email info@surrogacy4all.com. We look forward to hearing from you.
Surrogacy4All is a unique international surrogacy service targeted at providing state of the art IVF and surrogacy services to Intended Parents irrespective of age, sex or color, at the lowest possible cost in the world.
Secret Guide to Minimizing Surrogacy Costs
All Rights Reserved to Surrogacy4all